A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, E. F. Smit, D. Planchard, D. W. Kim, J. Cadranel, T. De Pas, F. Dunphy, K. Udud, M. J. Ahn, N. H. Hanna, J. H. Kim, J. Mazieres, S. W. Kim, P. Baas, E. Rappold, S. Redhu, A. Puski, F. S. Wu, P. A. Jänne

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m2 i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.

Original languageEnglish
Article numbermdv072
Pages (from-to)894-901
Number of pages8
JournalAnnals of Oncology
Volume26
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Exanthema
Diarrhea
trametinib
Medical Futility
Asthenia

Keywords

  • Docetaxel
  • KRAS
  • MEK inhibitor
  • NSCLC
  • Progression-free survival
  • Trametinib

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). / Blumenschein, George R.; Smit, E. F.; Planchard, D.; Kim, D. W.; Cadranel, J.; De Pas, T.; Dunphy, F.; Udud, K.; Ahn, M. J.; Hanna, N. H.; Kim, J. H.; Mazieres, J.; Kim, S. W.; Baas, P.; Rappold, E.; Redhu, S.; Puski, A.; Wu, F. S.; Jänne, P. A.

In: Annals of Oncology, Vol. 26, No. 5, mdv072, 01.05.2015, p. 894-901.

Research output: Contribution to journalArticle

Blumenschein, GR, Smit, EF, Planchard, D, Kim, DW, Cadranel, J, De Pas, T, Dunphy, F, Udud, K, Ahn, MJ, Hanna, NH, Kim, JH, Mazieres, J, Kim, SW, Baas, P, Rappold, E, Redhu, S, Puski, A, Wu, FS & Jänne, PA 2015, 'A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)', Annals of Oncology, vol. 26, no. 5, mdv072, pp. 894-901. https://doi.org/10.1093/annonc/mdv072
Blumenschein, George R. ; Smit, E. F. ; Planchard, D. ; Kim, D. W. ; Cadranel, J. ; De Pas, T. ; Dunphy, F. ; Udud, K. ; Ahn, M. J. ; Hanna, N. H. ; Kim, J. H. ; Mazieres, J. ; Kim, S. W. ; Baas, P. ; Rappold, E. ; Redhu, S. ; Puski, A. ; Wu, F. S. ; Jänne, P. A. / A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). In: Annals of Oncology. 2015 ; Vol. 26, No. 5. pp. 894-901.
@article{7280bc5d14d4468ba230b4247e28be6b,
title = "A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)",
abstract = "Background: KRAS mutations are detected in 25{\%} of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m2 i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95{\%} CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95{\%} CI 0.52-1.83; P = 0.934). There were 10 (12{\%}) partial responses (PRs) in the trametinib arm and 5 (12{\%}) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20{\%} of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.",
keywords = "Docetaxel, KRAS, MEK inhibitor, NSCLC, Progression-free survival, Trametinib",
author = "Blumenschein, {George R.} and Smit, {E. F.} and D. Planchard and Kim, {D. W.} and J. Cadranel and {De Pas}, T. and F. Dunphy and K. Udud and Ahn, {M. J.} and Hanna, {N. H.} and Kim, {J. H.} and J. Mazieres and Kim, {S. W.} and P. Baas and E. Rappold and S. Redhu and A. Puski and Wu, {F. S.} and J{\"a}nne, {P. A.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1093/annonc/mdv072",
language = "English",
volume = "26",
pages = "894--901",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

AU - Blumenschein, George R.

AU - Smit, E. F.

AU - Planchard, D.

AU - Kim, D. W.

AU - Cadranel, J.

AU - De Pas, T.

AU - Dunphy, F.

AU - Udud, K.

AU - Ahn, M. J.

AU - Hanna, N. H.

AU - Kim, J. H.

AU - Mazieres, J.

AU - Kim, S. W.

AU - Baas, P.

AU - Rappold, E.

AU - Redhu, S.

AU - Puski, A.

AU - Wu, F. S.

AU - Jänne, P. A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m2 i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.

AB - Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. Patients and methods: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2: 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m2 i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. Results: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P=1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. Conclusion: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRASmutant- positive NSCLC.

KW - Docetaxel

KW - KRAS

KW - MEK inhibitor

KW - NSCLC

KW - Progression-free survival

KW - Trametinib

UR - http://www.scopus.com/inward/record.url?scp=84929071676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929071676&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv072

DO - 10.1093/annonc/mdv072

M3 - Article

AN - SCOPUS:84929071676

VL - 26

SP - 894

EP - 901

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

M1 - mdv072

ER -